Goldman likes Incyte in premarket analyst action

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

Array BioPharma (NASDAQ:ARRY) initiated with Overweight rating and $30 (76% upside) price target. Shares are up 9% premarket on late-stage Mektovi/Braftovi data.

Incyte (NASDAQ:INCY) added to Conviction List with a $111 (51% upside) price target at Goldman Sachs citing M&A possibilities. Shares up 3% premarket.

MEDNAX (NYSE:MD) upgraded to Buy at Citigroup.

Medtronic (NYSE:MDT) upgraded to Buy with a $100 (18% upside) price target at BTIG Research. Shares up 1% premarket.

Subscribe for full text news in your inbox